Chemed Corporation Stock Down 2.5% Since Reporting Q2 2018 Earnings
Image via Dwight Burdette/Wikimedia
Shares of Chemed Corporation
Chemed Corp’s second quarter earnings boosted investor sentiment, as the company beat expectations.
The company released its earnings report last week, posting consolidated results of $442 million in revenue, up 6.4%. GAAP diluted EPS was $3.27, with adjusted diluted EPS coming in at $2.81, an increase of 30.7%. The parent company ended the quarter with less cash and cash equivalents, dropping $1 million from $13.7 million at the end of Q1 2018 to $12.7 million in the second quarter.
Chemed Corp reduced its debt from $132.5 million at the end of Q1 2018 to $103.4 million at the end of Q2 2018. The company also has $310 million in borrowing capacity as part of the company’s five-year credit agreement.
VITAS earnings from patient revenue rose 4.2% to $297 million compared to the same period a year prior. The company’s admissions also increased 3.4% to 16,858, with the company’s net income rising 25.6%, excluding special items, to $31.8 million.
Roto-Rooter, the company’s residential plumbing division, had revenues increase by 11.3%, rising to $145 million on the quarter. Net income for the division rose 48.3% compared to the same period last year, up to $25.3 million. Adjusted EBITDA also increased 19.8% to $36.5 million.
Commercial drain cleaning remained a strong segment for Roto-Rooter, with the segment increasing revenue by 9.7%. Residential drain cleaning rose 12.5%, with water restoration rising 19.6% on the quarter.
Earnings guidance has been revised upward following the quarterly release. The company’s full-year, 2018 earnings will be between $11.35 and $11.55 per share. Guidance assumes a 25.5% tax rate. Adjusted earnings per diluted share are expected to be $8.43.
Roto-Rooter full-year revenue growth is expected to be between 12% and 13%, with job pricing rising 2%. The company’s core plumbing business is expected to grow, with the company’s forecasted EBITDA margins to be at 24% for the year.
VITAS revenue growth for the full-year will be within the 4% and 5% range, with billing limitations of $2.5 million in the second half of the year due to Medicare Cap.
Chemed Corp’s stock is up over 30% since the start of the year and rallied to a 1.03% gain on Tuesday.